A process for the synthesis of benzoxazinone containing compounds which may be useful precursors for synthesizing compounds for the treatment of cancer, is hereby disclosed.

A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.

A nonaqueous electrolyte composition containing at least one organic isocyanide of formula (I) RNC, wherein: R is selected from R.sup.1, (CH.sub.2).sub.nL, and NP(R.sup.1).sub.3; L is selected from carboxylic ester groups, S-containing groups, N-containing groups, and P-containing groups which are substituted by one, two or three R.sup.1; R.sup.1 is selected independently from C.sub.1-C.sub.10 alkyl, C.sub.3-C.sub.10 (hetero)cycloalkyl, C.sub.2-C.sub.10 alkenyl, C.sub.3-C.sub.7 (hetero)cycloalkenyl, C.sub.2-C.sub.10 alkynyl, C.sub.5-C.sub.7 (hetero)aryl, and C.sub.6-C.sub.13 (hetero)aralkyl, and n is an integer from 1 to 10; with proviso that C.sub.3-C.sub.10 (hetero)cycloalkyl is not morpholinyl.

A nonaqueous electrolyte composition containing at least one organic isocyanide of formula (I) RNC, wherein: R is selected from R.sup.1, (CH.sub.2).sub.nL, and NP(R.sup.1).sub.3; L is selected from carboxylic ester groups, S-containing groups, N-containing groups, and P-containing groups which are substituted by one, two or three R.sup.1; R.sup.1 is selected independently from C.sub.1-C.sub.10 alkyl, C.sub.3-C.sub.10 (hetero)cycloalkyl, C.sub.2-C.sub.10 alkenyl, C.sub.3-C.sub.7 (hetero)cycloalkenyl, C.sub.2-C.sub.10 alkynyl, C.sub.5-C.sub.7 (hetero)aryl, and C.sub.6-C.sub.13 (hetero)aralkyl, and n is an integer from 1 to 10; with proviso that C.sub.3-C.sub.10 (hetero)cycloalkyl is not morpholinyl.

A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.

Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides. ##STR00001##

Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides. ##STR00001##

The present invention is directed to methods for the asymmetric synthesis of esketamine. The present invention is further directed to key intermediates in the asymmetric esketamine synthesis. In one embodiment, the invention is an asymmetric synthesis of esketamine comprising the conversion of (S)-2-chloro-2-methoxy-3,4,5,6-5 tetrahydro-[1, 1-biphenyl]-3-yl carbamate to (S)-2-chloro-1-isocyanato-6-methoxy-1,2,3,4-tetrahydro-1,1-biphenyl.

The present invention is directed to methods for the asymmetric synthesis of esketamine. The present invention is further directed to key intermediates in the asymmetric esketamine synthesis. In one embodiment, the invention is an asymmetric synthesis of esketamine comprising the conversion of (S)-2-chloro-2-methoxy-3,4,5,6-5 tetrahydro-[1, 1-biphenyl]-3-yl carbamate to (S)-2-chloro-1-isocyanato-6-methoxy-1,2,3,4-tetrahydro-1,1-biphenyl.

A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.